Biomarkers in the Etiology of Idiopathic Intracranial Hypertension (BEHIND)
Idiopathic Intracranial Hypertension
About this trial
This is an interventional other trial for Idiopathic Intracranial Hypertension focused on measuring Idiopathic intracranial hypertension HII, Intracranial pressure elevation (ICP), Transverse venous sinus stenosis, Cerebral venous stenting, Blood biomarkers
Eligibility Criteria
Inclusion Criteria: 18 years and older Patients with newly diagnosed untreated HII (following the modified Dandy criteria) with normal CSF composition, abnormal CSF pressure at the lumbar puncture (>25 cm H2O), and significant pressure gradient at the level of the stenosis (≥8 mmHg) Presence of bilateral transverse sinus stenosis (or unilateral with hypoplastic contralateral sinus). Exclusion Criteria: Allergy to contrast media (nickel, titanium) Allergy or contraindication to antiplatelet agents Patient on anti-inflammatory treatment Chronic inflammatory disease History of intracranial venous thrombosis, cerebral hemorrhage, thrombophilia History of intracranial tumor Fulminant IIH with acute visual loss Optic nerve atrophy with papilledema (chronic IIH) Female being pregnant, breastfeeding, or planning to become pregnant in the next 3 months Major comorbidities with high procedural risk Life expectancy < 6 months Adult under guardianship or conservatorship or incapacitated Refusal of consent after receiving all necessary information Not covered by or not a beneficiary of the French social security system
Sites / Locations
- University Hospital of Montpellier - Gui de Chauliac
Arms of the Study
Arm 1
Experimental
Idiopathic intracranial hypertension (IHH) patient
IHH patient with bilateral stenosis of the transversal sinus